{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-045970","form_type":"8-K","ticker":"NEUP","cik":"0001191070","company_name":"Neuphoria Therapeutics Inc.","filed_at":"2025-05-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.721189+00:00","generated_at":"2026-05-20T23:42:11.877078+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Neuphoria Q1 update: BNC-210 Phase 3 topline due Q3 2025; cash runway into Q3 2026","bullets":["Cash runway extends into Q3 2026; no near-term financing risk stated.","Phase 3 AFFIRM-1 trial of BNC-210 for social anxiety disorder on track for topline readout in Q3 2025.","Partnered α7 nAChR PAM MK-1167 (Merck) in Phase 2 for Alzheimer's disease.","Phase 2b SYMPHONY trial for BNC-210 in PTSD planned after positive FDA End-of-Phase 2 meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-045970","json":"https://secwatch.observer/filing/0001213900-25-045970.json","markdown":"https://secwatch.observer/filing/0001213900-25-045970.md","text":"https://secwatch.observer/filing/0001213900-25-045970.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1191070/000121390025045970/0001213900-25-045970-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1191070/000121390025045970/ea0242929-8k_neuphoria.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T23:42:11.877078+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}